Mémantine (Ebixa®)

Van Marum, 2009, Update on the use of memantine in Alzheimer's disease, Neuropsychiatr Dis Treat, 5, 237, 10.2147/NDT.S4048 Sonkusare, 2005, Dementia of Alzheimer's disease and other neurodegenerative disorders - memantine, a new hope, Pharmacol Res, 51, 1, 10.1016/j.phrs.2004.05.005 Afssaps, Commission de transparence, 4 décembre 2002. Résumé des caractéristiques du produit Ebixa® (mémantine). www.afssaps.sante.fr [consultation le 1er semestre 2009]. Agence européenne du médicament (EMEA). Autorisation du 08/05/2008 Ebixa-H-C-463-X-42, II-41. www.emea.europa.eu [consultation le 1er semestre 2009]. Winblad, 1999, Memantine in severe dementia: results of the 9M-BEST study. Benefit and efficacy in severely demented patients during treatment with memantine, Int J Geriatr Psychiatry, 14, 135, 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0 Reisberg, 2003, Memantine in moderate to severe Alzheimer's disease, N Engl J Med, 348, 1333, 10.1056/NEJMoa013128 Tariot, 2004, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial, JAMA, 291, 317, 10.1001/jama.291.3.317 Peskind, 2006, Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial, Am J Geriatr Psychiatry, 14, 704, 10.1097/01.JGP.0000224350.82719.83 Van Dyck, 2007, A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease, Alzheimer Dis Assoc Disord, 21, 136, 10.1097/WAD.0b013e318065c495 Bakchine, 2008, Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6 month study, J Alzheimers Dis, 13, 97, 10.3233/JAD-2008-13110 Porsteinsson, 2008, Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial, Curr Alzheimer Res, 5, 83, 10.2174/156720508783884576 Aarsland, 2009, Memantine in patients with Parkinson's disease dementia or dementia with lewy bodies: a double-blind, placebo-controlled, multicentre trial, Lancet Neurol, 8, 613, 10.1016/S1474-4422(09)70146-2 Cummings, 2006, Behavioral effects of memantine in Alzheimer's disease patients receiving donepezil treatment, Neurology, 67, 57, 10.1212/01.wnl.0000223333.42368.f1 Gauthier, 2005, Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomized, controlled studies, Int J Geriatr Psychiatry, 20, 459, 10.1002/gps.1341 Hartmann, 2003, Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy, Int Clin Psychopharmacol, 18, 81, 10.1097/00004850-200303000-00003 Lopez, 2009, Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer's disease, J Neurol Neurosurg Psychiatry, 80, 600, 10.1136/jnnp.2008.158964 Riepe, 2006, Adding memantine to rivastigmine therapy in patients with mild-to-moderate Alzheimer's disease: results of a 12-week, open-label pilot study, Prim Care Companion J Clin Psychiatry, 8, 258, 10.4088/PCC.v08n0501 Wilcock, 2008, Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies, J Clin Psychiatry, 69, 341, 10.4088/JCP.v69n0302 Maidment, 2008, Efficacy of memantine on behavioural and psychological symptoms related to dementia: a systematic meta-analysis, Ann Pharmacother, 42, 32, 10.1345/aph.1K372 Mecocci, 2009, Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies, Int J Geriatr Psychiatry, 24, 532, 10.1002/gps.2226 Wimo, 2003, Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease, Pharmacoeconomics, 21, 327, 10.2165/00019053-200321050-00004 Haute Autorité de santé. La réévaluation des médicaments anti-Alzheimer, septembre 2007. www.has-sante.fr [consultation le 1er semestre 2009].